S-8599 Sorafenib, Free Base, >99%

Related Terms : [Bay 43-9006] [Nexavar]

  • Size
  • US $
  • £
  • ¥
  • 500 mg
  • 36
  • 31
  • 27
  • 4,000
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 49
  • 43
  • 37
  • 5,400
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 72
  • 63
  • 55
  • 8,000
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 155
  • 136
  • 118
  • 17,200
  • Add to Cart Qty:
  • In stock
  • 10 g
  • 260
  • 229
  • 199
  • 28,800
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 33 Other Countries
  • M.W. 464.82
  • C21H16ClF3N4O3
  • [284461-73-0]
  • M.I. 14: 8720

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 200 mg/mL; soluble in ethanol at 3.3 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

View the SDS for this product

  • This is the free base form of sorafenib; please see our product Sorafenib, p-Toluenesulfonate Salt, Cat. No. S-8502, for further technical information. It is the p-toluenesulfonate salt form, not the free base, that is used in the formulation of sorafenib for in vivo use.
  • Sorafenib is the active ingredient in the drug sold under the trade name Nexavar®. This drug has been approved in at least one country for use in patients with advanced renal cell cancer. NOTE: The sorafenib sold by LC Laboratories is NOT Nexavar®, and is NOT for human use.
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.